Press Release: Marcus Evans Discovery Summit 2015
9 January 2015
Ari Tolonen of Admescope Ltd on improving the quality of data in preclinical development
“It is time for pharma companies to focus more on the quality of data than on the amount of data from a single source,” according to Ari Tolonen, Chief Executive Officer & Chief Scientific Officer, Admescope Ltd. “The key is to focus on your strengths as a company and to complete it with the expertise of your partners. In this way, every entry point used for decision-making is of the highest quality possible,” he adds.
Admescope Ltd is a contract research organisation attending the marcus evans Discovery Summit 2015, in Lisbon, Portugal, 16 - 17 March 2015.
How could pharma companies improve their ADME studies? What would boost preclinical success?
In preclinical development, the key is to focus on your own strengths, and choose partners with strengths that complete the know-how needed for the best possible outcome. Meaning that all the data required for decision-making does not have to be from a single source; it should rather be from a high-quality source. This ensures that every decision made is based on the highest quality data.
What is unique with Admescope’s approach to in vitro and in vivo drug metabolism? Do pharma companies overlook any important areas?
The largest pharma and biotech companies are on all the major decision-making boards within the field, and are fully up-to-date with the important topics concerning drug discovery and development. Nevertheless, there seems to be quite a difference between companies in the way and when they run their preclinical metabolism studies.
Some companies could pay greater attention to more thorough estimation of metabolism from the early PK studies; the metabolite profiling, that nowadays comes easily from the same experiments, provides better information on how to evaluate and compare results from different species. If there are mechanistic differences between species they will be pointed out clearly.
What would bridge the gap between preclinical and clinical studies?
Everyone is looking for the answer to that question. At the moment, development of in vitro assays parallel with ADME proteomics, and translational modelling and simulation might have a key role. This would enable improvements in in vivo extrapolation and PBPK modelling. At the moment, in vitro to in vivo extrapolation of cytochrome P450 mediated hepatic metabolism is well established, whereas bridging pre-clinical data on non-CYP mediated metabolism, extrahepatic metabolism and transporters is more challenging. Also, the recent developments in analytical techniques (LC/MS/MS) already enable the use of microdosing with non-labeled compounds, meaning studies in the preclinical stage i.e. in a much earlier stage than microdosing is most often considered.
What are the upcoming scientific areas or technologies worth following? What should pharma companies prepare for?
Improved PBPK modelling and simulation systems, and lots of research related to those, as well as research bringing input parameters for these predictive systems. One of these is 3D cell models that could better mimic in vivo systems than traditional in vitro assays. This has been a hot topic in the field for a few years and I do expect further improvements.
Analytics could also make yet a further leap forward. In the future, throughput could be much higher, as well as the amount of data received from a single analysis. We may be able to not just track each candidate and if it is metabolised, but at the same time do profiling of what really happens on the biomarker side in the same sample.
Contact: Sarin Kouyoumdjian-Gurunlian, Press Manager, marcus evans, Summits Division
Tel: + 357 22 849 313
About the Discovery Summit 2015
The 15th annual Global Discovery Summit is the premium forum bringing elite buyers and sellers together. The two track summit offers early drug discovery and preclinical R&D professionals and specialist solution providers an intimate environment for a focused discussion of key new drivers shaping discovery research and development. The Summit includes presentations on exploiting current and emerging technologies, boosting pipeline productivity, and recognising the corporate culture aspects of innovation to tackle pharma’s productivity crisis.
The Pharma Network – marcus evans Summits group delivers peer-to-peer information on strategic matters, professional trends and breakthrough innovations.
Please note that the Summit is a closed business event and the number of participants strictly limited.
About Admescope Ltd
Admescope is a contract research organization (CRO) providing the pharmaceutical, biotechnology and veterinary industry with premium quality tailor made services to drug discovery & development in the area of ADME-Tox. The service offering is widely spread over the whole ADME-tox area, from highly tailored and optimised studies to High Throughput Screening (HTS). Admescope’s unique expertise lies in in vitro & in vivo drug metabolism; including metabolite profiling & identification, drug-drug interactions and quantitative bioanalysis.
About marcus evans Summits
marcus evans Summits are high level business forums for the world’s leading decision-makers to meet, learn and discuss strategies and solutions. Held at exclusive locations around the world, these events provide attendees with a unique opportunity to individually tailor their schedules of keynote presentations, case studies, roundtables and one-to-one business meetings. For more information, please visit